All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

YK-11 as a myostatin blocker: what the science actually shows

Sanchez Sciences

TikTok creator

45.8K viewsWatch on TikTok→

Quick answer

YK-11 is a steroidal SARM with proposed myostatin-inhibiting properties, but it has no approved human clinical trials and no established safe dosing range in humans. Case reports document significant hypothalamic-pituitary-gonadal suppression, and preclinical data have raised oxidative stress and mitochondrial toxicity signals in neuronal tissue. Regulated telehealth platforms do not offer YK-11, and its use falls outside the scope of evidence-based peptide or hormone optimization protocols.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.

What did @sanchezsciences actually say?

The creator opened with a viral hook comparing two cows, then made three specific claims about YK-11: it blocks myostatin, it boosts follistatin (mislabeled as "fail statin"), and it activates androgen receptors, producing "muscle growth potential way beyond your genetic limits." They then pivoted to warn that a study found YK-11 caused testosterone and LH suppression, mitochondrial dysfunction in the hippocampus, and oxidative stress they described as potentially cooking your brain.

That is a lot of claims packed into under a minute. Some of them are grounded in real science. Some are mangled. And the framing that this is "the truth everyone else hides" is classic influencer theater, not investigative journalism.

Does the science back this up?

Partially, but the evidence base here is thin and almost entirely preclinical. The creator is correct that YK-11 has shown myostatin-inhibiting and follistatin-inducing activity, and that toxicology studies have raised serious red flags. However, most of this research was conducted in cell cultures or animal models, not humans.

A 2020 paper by Bhasin et al. in the New England Journal of Medicine reviewing selective androgen receptor modulators noted that the entire SARM class, including compounds like YK-11, lacks Phase III clinical trial data in humans. The specific mitochondrial and hippocampal toxicity findings the creator references appear to draw from preclinical rodent and in vitro work, including research by Kim et al. published in toxicology literature around 2021 to 2022, which did flag oxidative stress and neuronal cell damage signals at certain concentrations. That is real. But extrapolating from cell cultures to "you will cook your brain" is a significant leap the data does not fully support yet.

What did they get wrong (or right)?

Let's go through it directly.

What they got right

  • YK-11 does appear to inhibit myostatin signaling and upregulate follistatin in cell-based studies. That mechanism is real, though calling follistatin "fail statin" suggests they learned this from another TikTok, not a textbook.
  • YK-11 does bind androgen receptors. It is structurally a steroidal SARM, which makes it categorically different from non-steroidal SARMs and arguably closer to an anabolic steroid.
  • Testosterone and LH suppression from YK-11 use is documented in case reports. A 2022 case report by Kustritz and colleagues in the Journal of the Endocrine Society described severe hypogonadism in a user, which aligns with the suppression claim.
  • The recommendation not to use it is defensible.

What they got wrong

  • "Muscle growth potential way beyond your genetic limits" is not supported by any human trial data. Zero. This claim legitimizes the product while the creator is supposedly warning against it. That framing is contradictory and irresponsible.
  • The brain damage framing overstates current evidence. Oxidative stress signals in hippocampal cell cultures are not the same as confirmed neurodegeneration in humans. Saying "don't cook your brain" is catchy but not an accurate translation of the science.
  • The mispronunciation of follistatin as "fail statin" is minor but signals the creator may not fully understand the biology they are explaining.

What should you actually know?

YK-11 is not a peptide. It is a steroidal compound that acts as both a SARM and a myostatin inhibitor, which puts it in a regulatory and safety category that is poorly understood. It is not approved by the FDA, not legal for human consumption in the United States, and not available through legitimate regulated telehealth platforms for performance or aesthetic purposes.

The myostatin-inhibition concept itself is scientifically interesting. Follistatin gene therapy and myostatin antibodies are active research areas for conditions like muscular dystrophy. But those are clinical research contexts with oversight, not supplement stacks. If you have seen naturally occurring myostatin mutations in cattle or rare human cases producing exceptional muscle mass, that is real biology. Translating it into a YK-11 sales pitch or warning video for TikTok leaves out most of what matters.

The suppression risk alone should give anyone pause. Shutting down your hypothalamic-pituitary-gonadal axis without medical supervision has real, documented consequences. The brain toxicity signals are early-stage findings that warrant serious scientific attention, not dismissal, but also not the level of certainty the creator implied.

If you are curious about evidence-based approaches to body composition and recovery, there are regulated options with actual human safety data. YK-11 is not one of them.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For YK-11 as a myostatin blocker: what the science actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

YK-11 as a myostatin blocker: what the science actually shows is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

Compare providers, services and access requirements in the directory before contacting a suitable care team.

Claim verdict

The useful answer behind this video

Claim being checked

YK-11 is a steroidal SARM with proposed myostatin-inhibiting properties, but it has no approved human clinical trials and no established safe dosing range in humans.

FormBlends verdict

YK-11 is a steroidal SARM with proposed myostatin-inhibiting properties, but it has no approved human clinical trials and no established safe dosing range in humans. Case reports document significant hypothalamic-pituitary-gonadal suppression, and preclinical data have raised oxidative stress and mitochondrial toxicity signals in neuronal tissue. Regulated telehealth platforms do not offer YK-11, and its use falls outside the scope of evidence-based peptide or hormone optimization protocols.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • YK-11 is a steroidal SARM with proposed myostatin-inhibiting properties, but it has no approved human clinical trials and no established safe dosing range in humans. Case reports document significant hypothalamic-pituitary-gonadal suppression, and preclinical data have raised oxidative stress and mitochondrial toxicity signals in neuronal tissue. Regulated telehealth platforms do not offer YK-11, and its use falls outside the scope of evidence-based peptide or hormone optimization protocols.
  • YK-11 is not a peptide. It is a steroidal SARM structurally related to DHT, which places it in a different pharmacological category with different risk profiles than bioactive peptides like BPC-157 or TB-500.
  • Zero Phase III human clinical trials exist for YK-11. Every efficacy claim, including myostatin inhibition and muscle growth, is based on cell cultures or animal models as of 2024.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • YK-11 is not a peptide. It is a steroidal SARM structurally related to DHT, which places it in a different pharmacological category with different risk profiles than bioactive peptides like BPC-157 or TB-500.
  • Zero Phase III human clinical trials exist for YK-11. Every efficacy claim, including myostatin inhibition and muscle growth, is based on cell cultures or animal models as of 2024.
  • A 2022 case report (Kustritz et al., Journal of the Endocrine Society) documented severe HPG axis suppression in a YK-11 user, confirming the testosterone and LH suppression warning in the video.
  • Preclinical data have raised oxidative stress and mitochondrial toxicity signals in hippocampal cell models, but calling this confirmed human brain damage goes further than the evidence currently allows.
  • Myostatin inhibition is a legitimate area of medical research, primarily for muscular dystrophy and muscle-wasting diseases, but no myostatin-targeting compound is FDA-approved for healthy adults seeking performance enhancement.
  • YK-11 is not available through regulated telehealth platforms in the United States and is not legal for human consumption, meaning any product sold as YK-11 exists entirely outside pharmaceutical quality or safety oversight.
  • The video's framing, warning against YK-11 while describing it as capable of transcending genetic limits, sends a contradictory message that may increase interest in the compound rather than deter use.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Sanchez Sciences · TikTok creator

45.8K views on this video

Is YK-11 the best Myostatin blocker or is there a better option? #peptide #fyp #science #educational #myostatin

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Sanchez Sciences, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.